Skip to main content
VCEL
NASDAQ Life Sciences

Vericel 10-Q Confirms Q3 Net Income of $14.2M on $85.4M Revenue, $235.6M in Cash and Investments

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$49
Mkt Cap
$2.329B
52W Low
$28.95
52W High
$49.32
52W Position info
69% above low
Off High info
at 52W high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

VCEL sits 69% above its 52-week low of $28.95 on elevated volume (3.3× avg).

Summary

Vericel's Q3 10-Q confirms revenue of $85.4M (up 26.5%) and net income of $14.2M, with $235.6M in cash and investments and no debt drawn. It also details $8.8M of buybacks at an average of $40.08 and new CEO and director 10b5-1 selling plans.


Key Events · Earnings and Guidance · VCEL

  • Q3 Profit Jumps on 26.5% Revenue Growth

    Revenue rose to $85.4M from $67.5M and net income to $14.2M from $5.1M, lifting diluted EPS to $0.27 from $0.10.

  • Nine-Month Swing to Profitability

    Nine-month net income was $10.1M versus a $6.7M loss a year earlier, with operating income of $4.6M against a $11.4M operating loss.

  • Balance Sheet Funds Operations, No Debt Drawn

    Cash and equivalents of $133.5M plus $102.1M of investments; no outstanding borrowings under the $150.0M revolver and all covenants met.

  • Buybacks at $40.08 Average Leave $191.2M

    220,744 shares repurchased for $8.8M in Q3, an average of $40.08 per share, leaving $191.2M available under the $200M authorization.


Analysis · VCEL · Life Sciences

The 10-Q backs up this morning's earnings release with full statements: Q3 revenue of $85.4M (up 26.5%) and net income of $14.2M (up 179.1%) turned a $6.7M nine-month loss last year into $10.1M of profit this year. The balance sheet is the real story — $133.5M of cash plus $102.1M of investments funds operations for at least 12 months with no revolver borrowings, so there is no financing overhang. Against that, the company bought back 220,744 shares for $8.8M at an average of $40.08, well below today's $49.00, leaving $191.2M of the $200M authorization unused. The one item to flag is insider supply: the filing discloses new 10b5-1 plans for CEO Colangelo (up to 279,307 option shares from December 2026) and director McLaughlin (26,250 shares), which adds scheduled selling pressure over the next year.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VCEL was trading at $49.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $28.95 to $49.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VCEL - Latest Insights

VCEL
Nov 05, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $48.89
Real-time Price: $58.00 info
Change: +$9.11 (+19%) info
Market Cap: $2.973B info
VCEL
Nov 05, 2026, 7:55 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $58.00 info
Change: +$12.52 (+28%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 8:49 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info